Lurbinectedin is a drug used in the treatment of small cell lung cancer (SCLC) that has shown promise in clinical trials. According to DrugPatentWatch , the drug has been granted orphan drug status by the FDA and is currently in phase 3 clinical trials. The site also lists the drug's patent information and expiration date.
A study published in Targeted Oncology  evaluated the cost-effectiveness of lurbinectedin as a second-line treatment for SCLC. The study found that lurbinectedin was a cost-effective option compared to other treatments, such as topotecan, for patients with relapsed SCLC.
Another study published in the Journal of Clinical Medicine  evaluated the efficacy and safety of lurbinectedin in patients with SCLC. The study found that lurbinectedin showed promising results in terms of overall response rate and progression-free survival, with manageable side effects.
While more research is needed to fully understand the effectiveness of lurbinectedin compared to other therapies, these studies suggest that it may be a promising option for the treatment of SCLC.